Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Harrow Health, Inc.

Harrow Health, Inc. Changes Corporate Name to Harrow, Inc.
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Announces Second Quarter 2023 Financial Results
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Launches VIGAMOX® in the U.S.
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Prices $60 Million Public Offering of Common Stock
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Acquires Santen’s Branded Ophthalmic Portfolio
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Announces Proposed Public Offering of Common Stock
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Announces First Quarter 2023 Financial Results
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Announces Availability of Fortisite™ Formulations for In-Office Use
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Secures Capital to Close Recently Announced Acquisition
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Announces Proposed Offering of $100 Million of Senior Notes Due 2027 and “BB” Rating from Egan-Jones
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Health to Participate in H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Health Announces Second Quarter 2022 Financial Results
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Health to Announce Second Quarter 2022 Financial Results on August 9, 2022
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Health Announces Launch of IOPIDINE® 1% and MAXITROL® in the United States
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Health Announces First Quarter 2022 Financial Results
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Health to Participate in B. Riley Securities’ Annual Neuro & Ophthalmology Investor Conference
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Health to Announce First Quarter 2022 Financial Results on May 5, 2022
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Health Announces Appointments to Its Board of Directors
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Health to Announce Fourth Quarter and Year-End 2021 Financial Results on March 10, 2022
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Health Announces FDA Acceptance of New Drug Application for AMP-100
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Health to Present at Aegis Virtual Conference
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Health Publishes Corporate Transparency Report
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Health to Participate in H.C. Wainwright BioConnect Conference
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Health Acquires U.S. Commercial Rights to Four Branded Eye Drops
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Health Added to the Nasdaq Biotechnology Index
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Health Announces Third Quarter 2021 Financial Results
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Harrow Health to Announce Third Quarter 2021 Financial Results on November 9, 2021
From Harrow Health, Inc.
Via Business Wire
Tickers HROW
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.